Trial Profile
A Phase I, Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Intravenous Aflibercept in Combination With Intravenous Docetaxel Administrated Every 3 Weeks in Chinese Patients With Advanced Solid Malignancies.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Aflibercept (Primary) ; Docetaxel (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 12 Jan 2012 Actual end date (Dec 2011) added as reported by ClinicalTrials.gov.
- 12 Jan 2012 Actual patient number is 20 according to ClinicalTrials.gov.
- 12 Jan 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.